A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)

A Multicenter, Cross-sectional Study to Evaluate Plasma ApoB-48 Concentration Among Korean Diabetic Patients (With Normal to Moderately High LDL-C Levels)

This study will evaluate whether fasting/postprandial serum ApoB-48 levels are increased in diabetic participants compared to nondiabetic participants with the same range of serum LDL-C levels, and whether ApoB-48 levels can be used, along with LDL-C levels, to identify potential cardiovascular disease risk.

Inclusion criteria:

• Participant has an LDL-C ranging from ≥100 mg/dL to <160 mg/dL.
• Patient has a triglyceride (TG) level of ≤500 mg/dL.

Exclusion Criteria:

• Participant treated with a lipid-lowering agent in the 6 weeks prior to Visit 1 (screening period).
• Participant has active liver disease or persistent unexplained serum transaminase elevations (≥2 x the upper limit of normal [ULN])
• Participant has increased creatine kinase (CK) (≥2 x ULN).
• Participant has a history of type 1 diabetes mellitus, ketoacidosis, or gestational diabetes mellitus.
• Participant has a history of alcohol and/or drug abuse.